Mavacamten had been FDA approved on the basis of the EXPLORER-HCM trial's finding that the drug resulted in better functional ...

A federal judge said Amgen must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders ...

Eversource Energy expects to incur an aggregate net loss on the completion of its offshore wind business divesture of $520 ...

U.S homebuilder KB Home said on Monday its finance chief Jeff Kaminski has decided to retire in early 2025, after more than ...

Family Heart Foundation unveiled the Cholesterol Connect program for LDL-C Awareness Day, aiming to make it easier for people ...

Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report) today and set a price target of ...

Relative to its pharma competitors, Pfizer holds a leading market share of 9.9% as of Q2 2024, ahead of Abbott Laboratories ...

On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to the approval letter, “Pavblu is indicated for ...

Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.

The innovative program from the Family Heart Foundation includes being able to order a free test kit for an at-home blood ...

In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...